<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03426943</url>
  </required_header>
  <id_info>
    <org_study_id>69HCL17_0014</org_study_id>
    <secondary_id>2017-A03366-47</secondary_id>
    <nct_id>NCT03426943</nct_id>
  </id_info>
  <brief_title>Endotoxins and Cytokines Removal During Continuous Hemofiltration With oXiris™</brief_title>
  <acronym>ECRO</acronym>
  <official_title>Endotoxins and Cytokines Removal During Continuous Hemofiltration With oXiris™</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hospices Civils de Lyon</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Baxter Healthcare Corporation</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Hospices Civils de Lyon</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Sepsis is a major cause of death in Intensive Care Units and therefore finding new therapies
      to improve survival rates and limit morbidity is a major goal. Over the past decades, blood
      purification has been proposed as an adjuvant therapy for sepsis. The goal of blood
      purification is to restore the immune homeostasis and efficiency through the removal of
      bacterial products including endotoxins, broad-spectrum cytokines and other inflammatory
      mediators. Indeed, the large and overwhelmed release of these mediators in the early phase of
      sepsis may induce multiple organ failure syndrome. In 2017, different techniques are proposed
      for blood purification. Among them, the highly adsorptive membrane, oXiris™, seems promising.
      This membrane can be used in case of Acute Kidney Injury associated with sepsis and exhibits
      enhanced blood purification capacities. Previous studies on animals have already proven that
      this membrane can remove broad-spectrum cytokines but also endotoxins from the blood. This
      ability to remove endotoxins is particularly interesting since endotoxins are believed to be
      the trigger of the immune cascade at the initiation of sepsis.

      The lack of clinical evidence is the main limit to a wider use of this membrane. Therefore,
      the aim of the present clinical trial is to characterize the blood purification properties of
      the membrane in a human clinical setting. The oXiris™ membrane is specifically designed to
      improve the adsorptive capacities of the polyacrylonitrile-based AN69 membrane. Its extremely
      rich coating of polyethyleneimine (PEI) gives the membrane the ability to bind and remove not
      only cytokines but also endotoxins due to the positive charges of PEI at the surface of the
      membrane. The tested hypothesis is that the oXiris™ filter allows for a greater endotoxin and
      cytokine removal compared to a standard polysulfone (&quot;PrismafleX HF1400&quot;) filter in patients
      with septic shock.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 21, 2018</start_date>
  <completion_date type="Anticipated">March 21, 2022</completion_date>
  <primary_completion_date type="Anticipated">December 21, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Interleukin 6 (IL-6) plasmatic concentration</measure>
    <time_frame>24 hours after the initiation of CVVH</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Endotoxin plasmatic mass concentration</measure>
    <time_frame>24 hours after the initiation of CVVH</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pre-filter plasma endotoxin mass</measure>
    <time_frame>At initiation of CCVH (H0) then 1, 4, 12 and 24 hours after the initiation of CVVH</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pre-filter plasma endotoxin activity</measure>
    <time_frame>At initiation of CCVH (H0) then 1, 4, 12 and 24 hours after the initiation of CVVH</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Post-filter plasma endotoxin mass</measure>
    <time_frame>1, 4, 12 and 24 hours after the initiation of CVVH</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Post-filter plasma endotoxin activity</measure>
    <time_frame>1, 4, 12 and 24 hours after the initiation of CVVH</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pre-filter plasma cytokine level</measure>
    <time_frame>At initiation of CCVH (H0) then 1, 4, 12 and 24 hours after the initiation of CVVH</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Post-filter plasma cytokine level</measure>
    <time_frame>1, 4, 12 and 24 hours after the initiation of CVVH</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ultrafiltrate cytokine level</measure>
    <time_frame>1, 4, 12 and 24 hours after the initiation of CVVH</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pre-filter plasma lipids level</measure>
    <time_frame>At initiation of CCVH (H0) then 1, 4, 12 and 24 hours after the initiation of CVVH</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Post-filter plasma lipids level</measure>
    <time_frame>1, 4, 12 and 24 hours after the initiation of CVVH</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pre-filter plasma Procalcitonin level</measure>
    <time_frame>At initiation of CCVH (H0) then 1, 4, 12 and 24 hours after the initiation of CVVH</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Post-filter plasma Procalcitonin level</measure>
    <time_frame>1, 4, 12 and 24 hours after the initiation of CVVH</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pre-filter plasma Phospholipid Transfer Protein level</measure>
    <time_frame>At initiation of CCVH (H0) then 1, 4, 12 and 24 hours after the initiation of CVVH</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Post-filter plasma Phospholipid Transfer Protein level</measure>
    <time_frame>1, 4, 12 and 24 hours after the initiation of CVVH</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pre-filter plasma Cholesteryl Ester Transfer Protein level</measure>
    <time_frame>At initiation of CCVH (H0) then 1, 4, 12 and 24 hours after the initiation of CVVH</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Post-filter plasma Cholesteryl Ester Transfer Protein level</measure>
    <time_frame>1, 4, 12 and 24 hours after the initiation of CVVH</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pre-filter plasma lipopolysaccharide (LPS) Binding Protein level</measure>
    <time_frame>At initiation of CCVH (H0) then 1, 4, 12 and 24 hours after the initiation of CVVH</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Post-filter plasma LPS-Binding Protein level</measure>
    <time_frame>1, 4, 12 and 24 hours after the initiation of CVVH</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Norepinephrine requirements</measure>
    <time_frame>4, 12 and 24 hours after the initiation of CVVH</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fluids infused</measure>
    <time_frame>4, 12 and 24 hours after the initiation of CVVH</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient survival</measure>
    <time_frame>At day 7</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient survival</measure>
    <time_frame>At day 30</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient survival</measure>
    <time_frame>At day 90</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Comparison of the results obtained on the above-mentioned parameters, according to the type of bacteria identified from standard care microbiological exams.</measure>
    <time_frame>At day 7</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Septic Shock</condition>
  <condition>Peritonitis</condition>
  <arm_group>
    <arm_group_label>CVVH using oXiris™ filter</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients included in this arm will have renal replacement therapy by performing Continuous Veno-Venous Hemofiltration (CVVH) using oXiris™ membrane.
They will also have arterial blood sampling and ultrafiltrate sampling during the CVVH.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CVVH using PrismafleX HF1400 filter</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients included in this arm will have renal replacement therapy by performing CVVH using a standard polysulfone filter (PrismafleX HF1400).
They will also have arterial blood sampling and ultrafiltrate sampling during the CVVH.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Arterial blood sampling</intervention_name>
    <description>All patients will have arterial blood sampling to assess pre-filter and post-filter plasma endotoxin mass and activity and plasma cytokine levels</description>
    <arm_group_label>CVVH using PrismafleX HF1400 filter</arm_group_label>
    <arm_group_label>CVVH using oXiris™ filter</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Ultrafiltrate sampling</intervention_name>
    <description>All patients will have ultrafiltrate sampling to assess cytokine levels</description>
    <arm_group_label>CVVH using PrismafleX HF1400 filter</arm_group_label>
    <arm_group_label>CVVH using oXiris™ filter</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>CVVH using oXiris™ filter</intervention_name>
    <description>Patients included in the experimental arm will have renal replacement therapy by performing CVVH using oXiris™ filter</description>
    <arm_group_label>CVVH using oXiris™ filter</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>CVVH using PrismafleX HF1400 filter</intervention_name>
    <description>Patients included in the experimental arm will have renal replacement therapy by performing CVVH using PrismafleX HF1400 filter</description>
    <arm_group_label>CVVH using PrismafleX HF1400 filter</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female aged ≥ 18 years old,

          -  &quot;Early&quot; septic shock (in the first 12 hours after Intensive Care Unit (ICU) admission
             or readmission in the ICU after surgery), with lactatemia &gt; 2 mmol/L and
             norepinephrine needs &gt; 0.2 µg/kg/min 2 hours after the end of the initial surgery (to
             ensure that a potential anesthesia effect as disappeared),

          -  Secondary to a community-acquired or a nosocomial peritonitis (secondary or tertiary
             but not primary peritonitis),

          -  AKI KDIGO ≥ stage 2 or another indication for renal replacement therapy, according to
             the clinician in charge (if baseline creatinine is unknown, KDIGO ≥ stage 2 can be
             defined by a serum creatinine ≥ 2-fold the normal creatinine for age, gender, and
             ethnicity).

        Exclusion Criteria:

          -  Inability to obtain informed consent from the patient or next of kin,

          -  Actual participation in another interventional study,

          -  Contraindications to citrate,

          -  Allergy to heparin,

          -  Pregnant or breastfeeding woman,

          -  Neutropenia &lt; 0.5 G/L resulting from chemotherapy or other iatrogenic causes

          -  Patient receiving immunosuppressive therapy, long-term corticosteroids, therapeutic
             antibodies, chemotherapy in the last 6 months (whatever the dose),

          -  Patient with innate or acquired immune deficiency (for example severe combined
             immunodeficiency, HIV or AIDS)

          -  Onco-hematological disease (lymphoma, leukemia, myeloma) treated within the last 5
             years (but inclusion of a patient with solid cancer who did not receive chemotherapy
             during the past 6 months is possible),

          -  Patient with expected ICU length of stay &lt; 48 hours,

          -  Patient for whom a limitation of active care was pronounced at the time of enrollment,

          -  Patient with no social security insurance, with restricted liberty, or under legal
             protection.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Thomas RIMMELE, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospices Civils de Lyon</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Thomas RIMMELE, MD, PhD</last_name>
    <phone>+33 (0)4 72 11 69 88</phone>
    <email>thomas.rimmele@chu-lyon.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Valérie CERRO, CRA</last_name>
    <phone>+33 (0)4.72.11.69.86</phone>
    <email>valerie.cerro01@chu-lyon.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Hopital Universitaire de Clermont Ferrand</name>
      <address>
        <city>Clermont-Ferrand</city>
        <zip>63003</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jean-Michel CONSTANTIN</last_name>
      <email>jmconstantin@chu-clermontferrand.fr</email>
    </contact>
    <investigator>
      <last_name>Jean-Michel CONSTANTIN</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU Francois Mitterrand</name>
      <address>
        <city>Dijon</city>
        <zip>21033</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jean-Pierre QUENOT</last_name>
      <phone>03 80 20 31 95</phone>
      <phone_ext>+33</phone_ext>
      <email>jean-pierre.quenot@chu-dijon.fr</email>
    </contact>
    <investigator>
      <last_name>Jean-Pierre QUENOT</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU Dijon - Bocage central</name>
      <address>
        <city>Dijon</city>
        <zip>21079</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Belaïd BOUHEMAD</last_name>
      <phone>03 80 29 35 28</phone>
      <phone_ext>+33</phone_ext>
      <email>belaid.bouhemad@chu-dijon.fr</email>
    </contact>
    <investigator>
      <last_name>Belaïd BOUHEMAD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>L'Hôpital Nord-Ouest - Villefranche sur Saone</name>
      <address>
        <city>Gleizé</city>
        <zip>69400</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kevin CHAULIER</last_name>
      <phone>04 74 09 69 55</phone>
      <phone_ext>+33</phone_ext>
      <email>kchaulier@lhopitalnordouest.fr</email>
    </contact>
    <investigator>
      <last_name>Kevin CHAULIER</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Anesthesia and Critical Care Medicine Department - Edouard Herriot Hospital</name>
      <address>
        <city>Lyon</city>
        <zip>69003</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Thomas RIMMELE, MD, PhD</last_name>
      <phone>+33 (0)4 72 11 69 88</phone>
      <email>thomas.rimmele@chu-lyon.fr</email>
    </contact>
    <contact_backup>
      <last_name>Valérie CERRO, CRA</last_name>
      <phone>+33 (0)4.72.11.69.86</phone>
      <email>valerie.cerro01@chu-lyon.fr</email>
    </contact_backup>
    <investigator>
      <last_name>Thomas RIMMELE, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Clinique de la Sauvegarde</name>
      <address>
        <city>Lyon</city>
        <zip>69337</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Etienne HAUTIN</last_name>
      <phone>04 72 17 23 18</phone>
      <phone_ext>+33</phone_ext>
      <email>hautin.etienne@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Etienne HAUTIN</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpital Pasteur 2 - Hôpital Universitaire de Nice</name>
      <address>
        <city>Nice</city>
        <zip>06000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Carole ICHAI</last_name>
      <phone>04 92 03 36 27</phone>
      <phone_ext>+33</phone_ext>
      <email>carole.ichai@unice.fr</email>
    </contact>
    <investigator>
      <last_name>Carole ICHAI</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hopital Haut Lévèque - CHU Bordeaux</name>
      <address>
        <city>Pessac</city>
        <zip>33600</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Olivier JOANNES-BOYAU</last_name>
      <phone>05 57 65 68 66</phone>
      <phone_ext>+33</phone_ext>
      <email>olivier.joannes-boyau@chu-bordeaux.fr</email>
    </contact>
    <investigator>
      <last_name>Olivier JOANNES-BOYAU</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>May 2019</verification_date>
  <study_first_submitted>February 2, 2018</study_first_submitted>
  <study_first_submitted_qc>February 2, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">February 8, 2018</study_first_posted>
  <last_update_submitted>May 28, 2019</last_update_submitted>
  <last_update_submitted_qc>May 28, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">May 30, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Peritonitis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

